

## Enrolment

Assessed for eligibility ( $N = 3558$ )

Excluded ( $N = 967$ )\*

Randomized ( $N = 2591$ )

## Randomization

Randomized to chemotherapy alone ( $N = 1290$ )

- Received allocated treatment ( $N = 1270$ )
- Did not receive allocated treatment
  - No study drug received ( $N = 18$ )
  - Received bevacizumab ( $N = 2$ )

Randomized to chemotherapy plus bevacizumab ( $N = 1301$ )

- Received allocated treatment ( $N = 1286$ )
- Did not receive allocated treatment
  - No study drug received ( $N = 14$ )
  - Received no bevacizumab ( $N = 1$ )

## Analysis

Analyzed for efficacy ( $N = 1290$ )  
Analyzed for safety ( $N = 1271$ )

Analyzed for efficacy ( $N = 1301$ )  
Analyzed for safety ( $N = 1288$ )

## Follow-up

- Alive in follow-up/survival follow-up ( $N = 1001$ )
- Lost to follow-up ( $N = 140$ )
- Death ( $N = 149$ )

- Alive in follow-up/survival follow-up ( $N = 1047$ )
- Lost to follow-up ( $N = 110$ )
- Death ( $N = 144$ )